

Xavier Ghislain LÃ©on Victor Pouwels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8886573/publications.pdf>

Version: 2024-02-01

23
papers

165
citations

1307366

7
h-index

1281743

11
g-index

24
all docs

24
docs citations

24
times ranked

223
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of the TRansparent Uncertainty ASsessment (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. <i>Pharmacoeconomics</i> , 2020, 38, 205-216.	1.7	23
2	Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?. <i>Value in Health</i> , 2019, 22, 799-807.	0.1	14
3	Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 887-894.	1.7	13
4	Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2020, 38, 431-441.	1.7	12
5	Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1354-1365.	0.8	10
6	Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey. <i>Value in Health</i> , 2022, 25, 473-479.	0.1	9
7	Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 485-498.	1.1	8
8	Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1195-1207.	1.7	8
9	Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 655-667.	1.7	8
10	Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 917-927.	1.7	7
11	Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. <i>Medical Decision Making</i> , 2020, 40, 1003-1019.	1.2	7
12	Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands. <i>PLoS ONE</i> , 2020, 15, e0230909.	1.1	7
13	Trifluridine+Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 285-288.	1.7	5
14	The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry. <i>Acta Oncologica</i> , 2020, 59, 82-89.	0.8	5
15	Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2021, 39, 171-180.	1.7	4
16	Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands. <i>Value in Health</i> , 2021, 24, 668-675.	0.1	4
17	State of the ART? Two New Tools for Risk Communication in Health Technology Assessments. <i>Pharmacoeconomics</i> , 2021, 39, 1185-1196.	1.7	4
18	Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation. <i>Value in Health</i> , 2021, 24, 1126-1136.	0.1	4

#	ARTICLE	IF	CITATIONS
19	Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care. PLoS ONE, 2022, 17, e0260978.	1.1	4
20	An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. Acta Oncologica, 2020, 59, 1123-1130.	0.8	3
21	Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for) Tj ETQq 1.1 0.7843i4 rgBT	1.1	0
22	Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 533-543.	1.7	2
23	Response to Comment on "Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal" Pharmacoeconomics, 2020, 38, 649-651.	1.7	0